Celsus Therapeutics PLC (NASDAQ:AKTX) has earned a consensus broker rating score of 5.00 (Strong Sell) from the one analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong sell recommendation.
Analysts have set a twelve-month consensus price target of $5.00 for the company, according to Zacks. Zacks has also given Celsus Therapeutics PLC an industry rank of 94 out of 265 based on the ratings given to related companies.
A number of research firms recently commented on AKTX. Canaccord Genuity set a $33.00 target price on shares of Celsus Therapeutics PLC and gave the stock a “buy” rating in a report on Monday, August 15th. Chardan Capital began coverage on shares of Celsus Therapeutics PLC in a report on Monday, July 11th. They issued a “sell” rating and a $5.00 target price on the stock.
An institutional investor recently bought a new position in Celsus Therapeutics PLC stock. NEA Management Company LLC purchased a new position in shares of Celsus Therapeutics PLC (NASDAQ:AKTX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 452,167 shares of the biopharmaceutical company’s stock, valued at approximately $6,100,000. Celsus Therapeutics PLC makes up 0.3% of NEA Management Company LLC’s holdings, making the stock its 27th largest position. NEA Management Company LLC owned 3.84% of Celsus Therapeutics PLC at the end of the most recent reporting period. Hedge funds and other institutional investors own 35.70% of the company’s stock.
Celsus Therapeutics PLC (NASDAQ:AKTX) traded down 1.35% during trading on Thursday, reaching $8.78. 3,092 shares of the company’s stock traded hands. Celsus Therapeutics PLC has a 1-year low of $7.63 and a 1-year high of $24.00. The stock has a 50-day moving average price of $9.42 and a 200 day moving average price of $12.98. The stock’s market capitalization is $103.39 million.
Celsus Therapeutics PLC Company Profile
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsus Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsus Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.